Exosome Diagnostics and Therapeutics Market Expected to Surge

Emerging potential of exosome-based liquid biopsy is a primary factor driving the growth of the market. The Exosome Diagnostics and Therapeutics market is expected to surge from $59 million in 2024 to $6.848 billion by 2032 with a compound annual growth rate of 108.9%. 

The exosome-based liquid biopsy is a non-invasive option for disease diagnosis, prognosis and treatment response across various health conditions. 

Technological advancements have also led to the evolution of biopsy techniques. Reduced procedure costs and easy disease monitoring are some of the advantages it offers over traditional methods. 

Exosomes have gained traction in clinical research as a source of biomarkers suitable for diagnostic applications because of their stability and ability to carry genetic material such as cellular DNA, mRNA, and miRNA.